Aptamer Group signs agreement worth up to £155,000

Aptamer Group

Aptamer Group plc (LON: APTA), the developer of novel Optimer® binders to enable innovation in the life sciences industry, has announced the signing of a new development contract with a rare disease biopharmaceutical company. The agreement, worth up to £155,000, focuses on developing two Optimer binders as critical reagents for therapeutic monitoring. Upon successful development, Aptamer could receive a significant undisclosed IP transfer fee for the use of the Optimers in clinical trial monitoring.

Dr Arron Tolley, Chief Executive Officer of Aptamer Group, commented: “This agreement further demonstrates our strategic model of leveraging fee-for-service revenue for the development of Optimer binders and potential licensing revenues.

With a healthy pipeline and increasing traction among both new and repeat customers, we are demonstrating our commercial strategy. These advancements align with our broader vision of driving shareholder value by pairing fee-for-service income with scalable licensing opportunities. We remain focused on delivering on our growth objectives and look forward to sharing updates on our continued progress.”

We’ll keep you in the loop!

Join 1,000's of investors who read our articles first

We don’t spam! Read our privacy policy for more info.

Share on:
Find more news, interviews, share price & company profile here for:

    Aptamer advances liver fibrosis therapy with targeted gene delivery

    Aptamer Group has identified a novel target using its Optimer® platform to deliver gene therapy directly to liver scarring cells.

    Aptamer signs licensing deal for Optimer®-Fc diagnostic reagent

    Aptamer Group has entered a funded development and licensing agreement with a global life sciences company to create an Optimer®-Fc reagent for diagnostic kits. The deal includes royalties on future sales, supporting Aptamer’s recurring revenue growth.

    Aptamer expands odour control collaboration with Unilever

    Aptamer Group plc has partnered with Unilever for a second Optimer program, aiming to innovate body odour control solutions in the personal care market.

    Aptamer secures repeat contracts and new licensing deals

    Aptamer Group plc announces promising new data on its Optimer therapeutic delivery platform for liver fibrosis, showcasing broad therapeutic potential across various diseases.

    Aptamer adapts Alzheimer’s test to ELISA and signs royalty deal

    Aptamer Group announces a breakthrough in Alzheimer's diagnostics with a new ELISA test utilising saliva samples, enhancing accessibility and rapid detection.

    Aptamer licences Optimer binders for swine vaccines

    Aptamer Group plc has secured a significant global licensing deal with the University of Glasgow, advancing synthetic binders for vaccines in swine health.

      Search

      Search